Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, and Celanese Corporation, a global specialty materials company, today provided an update on their collaboration to evaluate the synergies between their respective technologies in the field of nanoparticle-enabled drug delivery.
Together, the API nanoparticles produced through Nanoform’s CESS® technology and the Celanese VitalDose® EVA copolymer delivery technology for drug-eluting implants have the potential to enable enhanced sustained release properties by reducing the initial burst release of a drug, which is a persistent challenge in high drug load implants. The increased drug load enabled by the nanoformed particles also allows smaller implants with sustained release properties to be developed.
“We are delighted with these results,” said Christian Jones, CCO of Nanoform, “and are excited about the continued opportunity to explore not only the technical benefits that the combination of these two technologies offer but, more importantly, the benefits that they bring to patients.”
“We believe that the synergies in our technologies will enable more patient-centricity in drug development,” said Susan Rahe, Vice President at Celanese, “We look forward to our continued collaboration with Nanoform to further propel the innovation we provide to the industry”
The findings will be presented at the Biotech Outsourcing Strategies Conference in Basel on July 3, 2023. For more information, please visit https://nanoform.com/en/technologies-and-services/small-molecules/ or https://www.vitaldose.com.
Nanoform is an innovative nanoparticle medicine-enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform’s platform technologies. The company focuses on reducing clinical attrition and on enhancing drug molecules’ performance through its Nanoforming technologies and formulation services. Nanoform’s capabilities include GMP manufacturing, and its services span the small to large-molecule development space with a focus on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 744 1900. For more information, please visit www.nanoform.com.
Celanese Corporation is a global chemical leader in the production of differentiated chemistry solutions and specialty materials used in most major industries and consumer applications. Our businesses use the full breadth of Celanese’s global chemistry, technology and commercial expertise to create value for our customers, employees, shareholders and the corporation. As we partner with our customers to solve their most critical business needs, we strive to make a positive impact on our communities and the world through The Celanese Foundation. Based in Dallas, Celanese employs approximately 13,000 employees worldwide and had 2022 net sales of $9.7 billion. For more information about Celanese Corporation and its product offerings, visit www.celanese.com.
For further information, please contact respectively:
|Christian Jones Chief Commercial Officer email@example.com +44 7804 474771||Karen Chen Director, Marketing Karen.firstname.lastname@example.org|
For investor relations queries, please contact respectively:
|Henri von Haartman Director of Investor Relations email@example.com +46 7686 650 11|